OBJECTIVES: Our aim was to access clinical effectiveness of percutaneous coronary intervention (PCI) when added to optimal medical therapy (OMT) in older patients with stable coronary artery disease (CAD). BACKGROUND: While older patients with CAD are at increased risk for cardiac events compared with younger patients, it is unclear whether PCI may mitigate this risk more effectively than OMT alone or, alternatively, may be associated with more complications. METHODS: We conducted a pre-specified analysis of outcomes in stable CAD patients stratified by age and randomized toPCI+OMT or OMT alone in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. RESULTS: A total of 1,381 patients (60%) were <65 years of age (mean 56+/-6 years) and 904 patients (40%) were >or=65 years of age (mean 72+/-5 years). Achieved treatment targets for blood pressure, low-density lipoprotein cholesterol, adherence to diet and exercise, and angina-free status did not differ by age or treatment assignment. Among older patients, there was a 2- to 3-fold higher death rate, but similar rates of myocardial infarction, stroke, and major cardiac events compared with younger patients. The addition of PCI to OMT did not improve or worsen clinical outcomes in patients>or=65 years of age during a median 4.6 year follow-up. CONCLUSIONS: These data support adherence to American College of Cardiology/American Heart Association clinical practice guidelines that advocate OMT as an appropriate initial management strategy, regardless of age. (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE]; NCT00007657).
RCT Entities:
OBJECTIVES: Our aim was to access clinical effectiveness of percutaneous coronary intervention (PCI) when added to optimal medical therapy (OMT) in older patients with stable coronary artery disease (CAD). BACKGROUND: While older patients with CAD are at increased risk for cardiac events compared with younger patients, it is unclear whether PCI may mitigate this risk more effectively than OMT alone or, alternatively, may be associated with more complications. METHODS: We conducted a pre-specified analysis of outcomes in stable CAD patients stratified by age and randomized to PCI+OMT or OMT alone in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. RESULTS: A total of 1,381 patients (60%) were <65 years of age (mean 56+/-6 years) and 904 patients (40%) were >or=65 years of age (mean 72+/-5 years). Achieved treatment targets for blood pressure, low-density lipoprotein cholesterol, adherence to diet and exercise, and angina-free status did not differ by age or treatment assignment. Among older patients, there was a 2- to 3-fold higher death rate, but similar rates of myocardial infarction, stroke, and major cardiac events compared with younger patients. The addition of PCI to OMT did not improve or worsen clinical outcomes in patients>or=65 years of age during a median 4.6 year follow-up. CONCLUSIONS: These data support adherence to American College of Cardiology/American Heart Association clinical practice guidelines that advocate OMT as an appropriate initial management strategy, regardless of age. (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE]; NCT00007657).
Authors: Muhammad Munir; Jonathan Aliota; Amany Ahmed; Anwarullah Mohammed; Vei Vei Lee; Macarthur A Elayda; James M Wilson Journal: Tex Heart Inst J Date: 2011
Authors: Sheng-Chia Chung; Mark A Hlatky; David Faxon; Kodangudi Ramanathan; Dale Adler; Arshag Mooradian; Charanjit Rihal; Roslyn A Stone; Joyce T Bromberger; Sheryl F Kelsey; Maria Mori Brooks Journal: J Am Coll Cardiol Date: 2011-08-16 Impact factor: 24.094
Authors: Hye-Jeong Lee; Young Jin Kim; Jin Hur; Ji Won Lee; Yoo Jin Hong; Hee Yeong Kim; Hyuk-Jae Chang; Tae Hoon Kim; Byoung Wook Choi Journal: Int J Cardiovasc Imaging Date: 2014-01-23 Impact factor: 2.357
Authors: Steven P Sedlis; Pamela M Hartigan; Koon K Teo; David J Maron; John A Spertus; G B John Mancini; William Kostuk; Bernard R Chaitman; Daniel Berman; Jeffrey D Lorin; Marcin Dada; William S Weintraub; William E Boden Journal: N Engl J Med Date: 2015-11-12 Impact factor: 91.245
Authors: Madlen Uhlemann; Volker Adams; Karsten Lenk; Axel Linke; Sandra Erbs; Jennifer Adam; Holger Thiele; Thomas Hilberg; Matthias Gutberlet; Martin Grunze; Gerhard C Schuler; Sven Möbius-Winkler Journal: Trials Date: 2012-09-14 Impact factor: 2.279